Nav: Home

Australia currently on track to eliminate hepatitis C by 2030, but challenges remain for hepatitis B

October 31, 2017

New data released at this year's World Hepatitis Summit in Sao Paulo, Brazil (1-3 November) shows that Australia is currently on track to eliminate hepatitis C thanks to its huge efforts to enable population-wide access to treatment. However, the challenge will be to keep annual treatment numbers high enough to eliminate the virus by 2030. For hepatitis B, progress is slower and more challenges remain.

The latest estimate from the Polaris Observatory (Center for Disease Analysis Foundation, Lafayette, CO, USA), which has been verified by Australian experts, shows Australia had some 202,000 people living with chronic hepatitis C infection at the end of 2016. Thanks to a pioneering risk-sharing agreement between the Australian Government and Pharmaceutical companies for the new directly acting antiviral drugs (DAAs), beginning March 2016, all Australian adults are now able to access government-funded treatment. It is thought over 32,000 patients accessed treatment from March 2016 to December 2016, around 1 in 7 of the total infected population nationwide.

Following this agreement, huge numbers of people came forward for treatment immediately (some 5,000 in March 2016 alone). However, the number treated each month has steadily declined, from over 5,000 in March 2016 to less than 2,500 in March 2017, with signs the number will decrease further still. The Polaris estimate shows that Australia must treat around 20,000 patients with hepatitis C per year to reach the WHO elimination target it endorsed (a reduction of new hepatitis B and C infections by 90% and mortality by 65% by 2030). Polaris predicts annual treatment numbers for HCV could fall to 14,000 by 2018.

"Australia set off at a cracking pace on the journey to elimination of hepatitis C due to our unrestricted and easy access to treatment," says Helen Tyrell, Chief Executive Officer, Hepatitis Australia. "From March 2016, when the cures became available, to December of that year around 14% of all people living with hepatitis C commenced treatment. However, the pace has slowed dramatically over time."

She adds: "Worryingly, the latest estimates from the Polaris Observatory should be taken as a clear warning that the elimination of hepatitis C is unlikely to be achieved by 2030 if we continue 'business as usual'. What we need now is a rapid scale up of a suite of programs to help connect all people with hepatitis C to the new cures while also continuing to prioritise evidence-based prevention. Provided Australia invests in this work and maintains a strong partnership approach across government, the community, clinicians and researchers, we can reach the goal of elimination of hepatitis C by 2030."

Australia has a very high diagnosis rate (three quarters of those with hepatitis C know they are infected, compared to 44% across rich countries generally and 1 in 5 globally). Thus, it is essential that efforts are stepped up to bring those known to be infected into care and provided with treatment. However, many people were diagnosed years or sometimes decades ago, and were told at the time to go home and "not worry about it" due to lack of treatment options. Like all countries, Australia faces challenges to find many of these patients again and connect them with care.

There are signs of progress in key populations: thanks to DAA availability, the proportion of patients injecting drugs accessing hepatitis C care increased from 1-3% from 2012-2015 to 22% in 2016. Most States and Territories are developing programs for new treatment access in drug and alcohol services, and prisons, where around one in 3 prisoners nationwide are thought to be infected with HCV.

Furthermore, new DAAs that are effective across all genotypes of hepatitis C have recently become available on Australia's Pharmaceutical Benefits Scheme, making it even easier for treatment to be prescribed by non-specialists, including general practitioners who now write around a third of all prescriptions for DAAs.

"Australia has made a fantastic inroad into its hepatitis C epidemic, but the challenge ahead is to ensure all people with chronic hepatitis C are diagnosed and linked to care. Different approaches and models of care will be needed for different population groups to achieve this so that no group is left behind," concludes Tyrrell.

For hepatitis B, the challenges are very significant as the national response is not as well advanced as that for hepatitis C. The first National Hepatitis B Strategy was launched in 2010 some ten years after the first National Hepatitis C Strategy. Australia is succeeding in turning the tide on new infections among young people under 25 years due to an effective infant and adolescent hepatitis B vaccination program. However, with one in three of those estimated to be living with chronic hepatitis B not yet diagnosed and suboptimal monitoring (just one in six patients monitored for disease progression when all patients should be) and treatment rates (6% treated versus a national target of 15%) it is clear that a significant commitment will be required to achieve the 2030 elimination goals.

"Hepatitis B is clearly lagging well behind hepatitis C at present and Australia must accelerate efforts across the board," says Tyrrell. "We are hoping that The Third National Hepatitis B Strategy, currently in development, will be the catalyst to both articulate and invest in a range of priority actions urgently needed to get hepatitis B on a track towards elimination by 2030. Improving community knowledge and diagnosis of those in higher risk populations is a top priority combined with regular liver assessments for all people with chronic hepatitis B to help stop progression to serious liver disease, liver cancer and avoidable deaths from this often silent infection."
-end-


World Hepatitis Alliance

Related Hepatitis Articles:

Nanotechnology delivers hepatitis B vaccine
X-ray imaging shows that nanostructured silica acts as a protective vehicle to deliver intact antigen to the intestine so that it can trigger an immune response.
Checkmate for hepatitis B viruses in the liver
Researchers at Helmholtz Zentrum München and the Technical University of Munich, working in collaboration with researchers at the University Medical Center Hamburg-Eppendorf and the University Hospital Heidelberg, have for the first time succeeded in conquering a chronic infection with the hepatitis B virus in a mouse model.
How common is Hepatitis C infection in each US state?
Hepatitis C virus infection is a major cause of illness and death in the United States and injection drug use is likely fueling many new cases.
New strains of hepatitis C found in Africa
The largest population study of hepatitis C in Africa has found three new strains of the virus circulating in the general population in sub-Saharan Africa.
High stability of the hepatitis B virus
At room temperature, hepatitis B viruses (HBV) remain contagious for several weeks and they are even able to withstand temperatures of four degrees centigrade over the span of nine months.
Findings could lead to treatment of hepatitis B
Researchers have gained new insights into the virus that causes hepatitis B -- a life-threatening and incurable infection that afflicts more than 250 million people worldwide.
How to cure more hepatitis C patients
The cost of cures for hepatitis C have been prohibitive, but experts who served on an NAS panel have a solution that will save more patients and incentivize drug innovation.
Hepatitis C: A novel point-of-care assay
One of the major challenges identified by the WHO in efforts to eradicate the hepatitis C virus is the diagnosis of chronic cases that are generally asymptomatic.
Countries risk 'running out' of hepatitis C patients to treat, says World Hepatitis Alliance
The latest data on the global hepatitis C epidemic, released today at the World Hepatitis Summit in Sao Paulo, Brazil, reveal that most countries (especially high-income countries) are running out of patients to treat because of the low diagnosis rates worldwide.
Australia currently on track to eliminate hepatitis C by 2030, but challenges remain for hepatitis B
New data released at this year's World Hepatitis Summit in Sao Paulo, Brazil, shows that Australia is currently on track to eliminate hepatitis C thanks to its huge efforts to enable population-wide access to treatment.
More Hepatitis News and Hepatitis Current Events

Top Science Podcasts

We have hand picked the top science podcasts of 2019.
Now Playing: TED Radio Hour

Risk
Why do we revere risk-takers, even when their actions terrify us? Why are some better at taking risks than others? This hour, TED speakers explore the alluring, dangerous, and calculated sides of risk. Guests include professional rock climber Alex Honnold, economist Mariana Mazzucato, psychology researcher Kashfia Rahman, structural engineer and bridge designer Ian Firth, and risk intelligence expert Dylan Evans.
Now Playing: Science for the People

#541 Wayfinding
These days when we want to know where we are or how to get where we want to go, most of us will pull out a smart phone with a built-in GPS and map app. Some of us old timers might still use an old school paper map from time to time. But we didn't always used to lean so heavily on maps and technology, and in some remote places of the world some people still navigate and wayfind their way without the aid of these tools... and in some cases do better without them. This week, host Rachelle Saunders...
Now Playing: Radiolab

Dolly Parton's America: Neon Moss
Today on Radiolab, we're bringing you the fourth episode of Jad's special series, Dolly Parton's America. In this episode, Jad goes back up the mountain to visit Dolly's actual Tennessee mountain home, where she tells stories about her first trips out of the holler. Back on the mountaintop, standing under the rain by the Little Pigeon River, the trip triggers memories of Jad's first visit to his father's childhood home, and opens the gateway to dizzying stories of music and migration. Support Radiolab today at Radiolab.org/donate.